EHA Library - The official digital education library of European Hematology Association (EHA)

HYDROXYUREA INHIBITS MYELOID DIFFERENTIATION VIA NITRIC OXIDE SYNTHASE
Author(s): ,
Tijana Subotički
Affiliations:
Laboratory of neuroendocrinology,Institute for Medical Research, University of Belgrade,Belgrade,Serbia
,
Olivera Mitrović Ajtić
Affiliations:
Laboratory of neuroendocrinology,Institute for Medical Research, University of Belgrade,Belgrade,Serbia
,
Miloš Diklić
Affiliations:
Laboratory of experimental hematology,Institute for Medical Research, University of Belgrade,Belgrade,Serbia
,
Sanja Vignjević Petrinović
Affiliations:
Laboratory of neuroendocrinology,Institute for Medical Research, University of Belgrade,Belgrade,Serbia
,
Mirela Budeč
Affiliations:
Laboratory of neuroendocrinology,Institute for Medical Research, University of Belgrade,Belgrade,Serbia
,
Dragoslava Djikić
Affiliations:
Laboratory of neuroendocrinology,Institute for Medical Research, University of Belgrade,Belgrade,Serbia
,
Juan Santibanez
Affiliations:
Laboratory of experimental hematology,Institute for Medical Research, University of Belgrade,Belgrade,Serbia
Vladan Čokić
Affiliations:
Laboratory of experimental hematology,Institute for Medical Research, University of Belgrade,Belgrade,Serbia
(Abstract release date: 05/18/17) EHA Library. Subotički T. 05/18/17; 182853; PB2140
Dr. Tijana Subotički
Dr. Tijana Subotički
Contributions
Abstract

Abstract: PB2140

Type: Publication Only

Background

Hydroxyurea and nitric oxide (NO) inhibit erythroid differentiation, while hydroxyurea is NO-releasing agent used in therapy of sickle cell diseases.

Aims
To study the mechanism of hydroxyurea inhibition of erythroid differentiation by exploring NO synthase (NOS) dependence.

Methods

The erythroid differentiation is studied by methylcellulose colony assay in mice, whereas presence and activation of endothelial NOS (eNOS) by immunocytochemistry and immunoblotting, respectively in K562 erythroleukemic cell line.

Results
In ex vivo experiments, mice exposed 7 days to hydroxyurea demonstrated significant decrease in the number of nucleated cells per femur, partially reversed by NOS inhibitor N-nitro L-arginine methyl ester hydrochloride (L-NAME). The same, but less prominent reduction has been observed with NO metabolites nitrite (NO2) and nitrate (NO3). Moreover, hydroxyurea demonstrated a large diminution in the number of bone marrow derived myeloid colony-forming unit -granulocyte/macrophage (CFU-GM), burst-forming-units-erythroid (BFU-E) and colony-forming unit-erythroid (CFU-E) colonies in methylcellulose cultures. L-NAME attenuated hydroxyurea reduction of myeloid and erythroid colonies, while by itself increased CFU-E and CFU-GM colonies and slightly BFU-E colonies. NO metabolites NO2 and NO3 generally inhibited myeloid and erythroid colonies, but the reduction was more prominent by NO2 compound. Moreover, the hematological parameters and weight (before and after treatment) of mice did not show any significant difference among studied groups. Hydroxyurea increased NO production and the number of eNOS positive K562 erythroleukemic cells, while phosphorylation of eNOS and activation of AKT/mTOR signaling was not blocked by phosphatidylinositol 3-kinase inhibition.

Conclusion

NO prodrug hydroxyurea demonstrated NOS dependence in inhibition of myeloid / erythroid differentiation, not influencing the hematological parameters.

Session topic: 25. Sickle cell disease

Keyword(s): Nitric oxide synthase, Myeloid differentiation, Hydroxyurea, Erythroid lineage

Abstract: PB2140

Type: Publication Only

Background

Hydroxyurea and nitric oxide (NO) inhibit erythroid differentiation, while hydroxyurea is NO-releasing agent used in therapy of sickle cell diseases.

Aims
To study the mechanism of hydroxyurea inhibition of erythroid differentiation by exploring NO synthase (NOS) dependence.

Methods

The erythroid differentiation is studied by methylcellulose colony assay in mice, whereas presence and activation of endothelial NOS (eNOS) by immunocytochemistry and immunoblotting, respectively in K562 erythroleukemic cell line.

Results
In ex vivo experiments, mice exposed 7 days to hydroxyurea demonstrated significant decrease in the number of nucleated cells per femur, partially reversed by NOS inhibitor N-nitro L-arginine methyl ester hydrochloride (L-NAME). The same, but less prominent reduction has been observed with NO metabolites nitrite (NO2) and nitrate (NO3). Moreover, hydroxyurea demonstrated a large diminution in the number of bone marrow derived myeloid colony-forming unit -granulocyte/macrophage (CFU-GM), burst-forming-units-erythroid (BFU-E) and colony-forming unit-erythroid (CFU-E) colonies in methylcellulose cultures. L-NAME attenuated hydroxyurea reduction of myeloid and erythroid colonies, while by itself increased CFU-E and CFU-GM colonies and slightly BFU-E colonies. NO metabolites NO2 and NO3 generally inhibited myeloid and erythroid colonies, but the reduction was more prominent by NO2 compound. Moreover, the hematological parameters and weight (before and after treatment) of mice did not show any significant difference among studied groups. Hydroxyurea increased NO production and the number of eNOS positive K562 erythroleukemic cells, while phosphorylation of eNOS and activation of AKT/mTOR signaling was not blocked by phosphatidylinositol 3-kinase inhibition.

Conclusion

NO prodrug hydroxyurea demonstrated NOS dependence in inhibition of myeloid / erythroid differentiation, not influencing the hematological parameters.

Session topic: 25. Sickle cell disease

Keyword(s): Nitric oxide synthase, Myeloid differentiation, Hydroxyurea, Erythroid lineage

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies